StemSation(TM) Reports Revenue Increase of 24% for the Quarter Ending June 30th, 2020

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BOCA RATON, FL / ACCESSWIRE / August 19, 2020 / StemSation International, Inc. (OTC PINK:STSN) – a pioneer in the emerging category of dietary supplements called Stem Cell Nutrition, reported revenues for the second quarter ending June 30th , 2020 of $65,405 compared to revenues of $52,675 for the first quarter ending March 31st, 2020, representing an increase of 24% increase.

As start-up expenses subside, overhead costs also decreased by 18% in the second quarter. Ray Carter, StemSation President & CEO commented, “We are pleased to see the positive trends in our financials despite the COVID-19 challenges. We continue to see further growth as we move through Q3 and accelerate our marketing efforts”.

StemSation creates and markets all-natural consumer health products that support the two most recently discovered biological systems of the human body – stem cells and endocannabinoids, releasing its first three novel products to support immune health and joint & muscle health.

StemSation continues to expand its product reach globally, currently executing plans to enter the Latin American markets before the end of 2020.

StemSation is a company with a long-term ‘health mission’, ambitious research goals, and innovative, holistic approaches to health & wellness, and healthy longevity. Our product line shows a new pathway to wellness.

ABOUT STEMSATION INTERNATIONAL, INC.
StemSation International, Inc. (OTC PINK:STSN) develops, manufactures and distributes natural wellness products that support the stem cell and endocannabinoid systems in the human body through using a direct selling model in which Independent Wellness Advocates (“IWAs”) advertise and sell its products directly to consumers. StemSation is headquartered in Boca Raton, Florida and its website can be located at www.stemsation.global.

SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company’s control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

FOR INFORMATION, PLEASE CONTACT:
Nicholas B. Panza, Vice President
StemSation International, Inc.
7777 Glades Road
Suite 203
Boca Raton, FL 33434
npanza@stemsationusa.com
(561) 245-7454

SOURCE: StemSation International, Inc.

View source version on accesswire.com:
https://www.accesswire.com/602316/StemSationTM-Reports-Revenue-Increase-of-24-for-the-Quarter-Ending-June-30th-2020

Staff

Recent Posts

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

9 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

9 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

12 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

12 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

12 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

12 hours ago